This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic Poised on Strong Fundamentals Despite Several Woes
by Zacks Equity Research
On Feb 23, we issued an updated research report on medical device major, Medtronic plc (MDT).
Omnicell: Q4 Report Disappoints, Aesynt Buyout Holds Promise
by Zacks Equity Research
On Feb 22, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL).
Patterson Companies (PDCO) Earnings Beat Estimates in Q3
by Zacks Equity Research
Patterson Companies Inc. (PDCO) reported third-quarter fiscal 2017 adjusted earnings of 58 cents per share from continuing operations, which came higher than the Zacks Consensus Estimate of 57 cents.
Fresenius Medical (FMS) Tops Earnings in Q4, View Upbeat
by Zacks Equity Research
Fresenius Medical Care AG & Co. KGAA (FMS) reported adjusted earnings of 63 cents per American Depositary Share (ADS) in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 61 cents.
Inovalon (INOV) Q4 Earnings In Line, Revenue Beat Estimates
by Zacks Equity Research
Inovalon Holdings, Inc. (INOV) reported fourth-quarter 2016 adjusted earnings of 2 cents per share, which came in line with the Zacks Consensus Estimate.
Align Expands Internationally with Dental Couture Buyout
by Zacks Equity Research
Align Technology (ALGN) has recently announced the acquisition of Dubai, UAE and Nicosia, Cyprus-based distributor, G.L. Dental Couture Limited.
Teleflex (TFX) Gains FDA Approval for TrapLiner Catheter
by Zacks Equity Research
Teleflex Incorporated (TFX) recently announced 510(k) clearance for its TrapLiner Catheter from the US FDA for a full fledged commercial launch in the country.
Henry Schein Inks Agreement for Rijuven's CardioSleeve
by Zacks Equity Research
Henry Schein, Inc. (HSIC) recently signed an exclusive distribution agreement with patient care platform designer Rijuven Corp. to sell the latter's CardioSleeve device
Wright Medical (WMGI) Posts Narrower-than-Expected Q4 Loss
by Zacks Equity Research
Wright Medical Group N.V. (WMGI) reported adjusted loss of 6 cents per share in the fourth quarter of 2016, narrower than loss of 8 cents reported in the year-ago quarter and the Zacks Consensus Estimate of a loss of 11 cents.
DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles
by Zacks Equity Research
DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.
Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View
by Zacks Equity Research
Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.
Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4
by Zacks Equity Research
Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.
Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View
by Zacks Equity Research
Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.
Henry Schein to Acquire SAS to Strengthen Dental Offerings
by Zacks Equity Research
Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).
DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues
by Zacks Equity Research
DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.
Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial
by Zacks Equity Research
Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial
Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.
DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4
by Zacks Equity Research
DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.
GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y
by Zacks Equity Research
GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.
Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT
by Zacks Equity Research
Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.
LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View
by Zacks Equity Research
Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View
by Zacks Equity Research
Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.
Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss
by Zacks Equity Research
Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.
Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.
CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4
by Zacks Equity Research
CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.